BioNexus Hub
← Roadmap  /  Track 4: RNA Biology & Epitranscriptomics  /  Integrative thinking

Integrative Thinking: Layering RNA-Level Evidence

Any single dataset is suggestive at best. The skill that separates a real bioinformatician from a button-pusher is combining independent lines of evidence, expression, binding, modification, structure, into one coherent, testable mechanism. This closing lesson of Track 4 teaches that reasoning: how to turn correlation into a credible story, tell direct targets from indirect ones, and know when you have actually shown causality.

🏆 Track 4 capstone 🔴 Advanced ⏱️ ~1.5 hr 📊 Reasoning

Before you start

Learning objectives

By the end of this lesson you will be able to: explain why each RNA method answers a different question, layer structure, binding, and modification evidence into a mechanism, and apply the reasoning rules that keep an integrative conclusion honest.

Each method answers a different question

You now have several RNA-level assays in your toolkit. The key insight is that each measures a different thing, and the mechanism only emerges when you read them together.

📈
Expression RNA-seq / DESeq2
Which transcripts change in abundance. (Track 3.)
🧲
Protein binding CLIP-seq
Which transcripts (and where) a specific protein directly binds.
🔬
Modification MeRIP / m6A-seq
Which transcripts and regions carry m6A (or another mark).
🧬
Structure SHAPE / icSHAPE
Which regions are paired or accessible.
🏭
Translation Ribo-seq
Which mRNAs are actually being translated, and how much.

How layering builds a mechanism

Take a concrete, well-supported example. Suppose you want to test the hypothesis "m6A destabilizes a set of transcripts via the reader YTHDF2." A single experiment cannot prove this. Layered evidence can build a strong case:

  1. Modification: MeRIP shows the transcripts are m6A-methylated.
  2. Perturbation + expression: knock down the writer METTL3; methylation drops and those same transcripts become more abundant and longer-lived (RNA-seq, ideally with RNA half-life measurement).
  3. Binding: CLIP of YTHDF2 shows it directly binds those methylated transcripts.
  4. Reader perturbation: knocking down YTHDF2 reproduces the stabilization, placing it downstream of the mark.

Now you have a mechanism: m6A → bound by YTHDF2 → faster decay. No single dataset says this. The convergence of an orthogonal modification map, a perturbation, a binding map, and a half-life change is what makes it credible. This is exactly the YTHDF2 decay pathway established in the field (Wang et al., 2014).

Decode the jargonDirect vs indirect target

A direct target is a transcript the protein or mark acts on physically. An indirect change is a downstream knock-on effect. After knocking down a writer, hundreds of genes may change in expression, but only the ones that are also methylated and also bound by the relevant reader are credible direct targets. Intersecting datasets is how you separate the two.

The reasoning rules that keep you honest

  • Correlation is not mechanism. "Methylated transcripts are also less stable" is a correlation. You need a perturbation (remove the writer/eraser/reader and watch the effect track) to argue causality.
  • Intersect to find direct targets. Overlap the differentially expressed genes with the methylation peaks and the CLIP binding sites. The intersection is your high-confidence set; genes in only one list are weaker.
  • Mind the resolutions. A ~100 nt MeRIP peak, a single-nucleotide CLIP site, and a gene-level expression value live at different scales. Integrate them carefully (e.g. at the transcript or region level), and do not over-interpret coincidental overlaps.
  • Watch confounders. Expression changes can masquerade as modification or binding changes if you do not normalize against the right control (the input for MeRIP, the size-matched input for eCLIP).
  • Independent lines beat one big dataset. Credibility comes from orthogonal methods agreeing, not from one assay run deeper.

⚠️ The trap: a long differential-expression list is not a mechanism

After perturbing an RNA regulator, you will get a big list of changed genes. Most are downstream and indirect. Presenting that whole list as "targets" overstates the result. The defensible claim is the small set supported by binding and modification and the expected direction of change after perturbation. Less, but proven, beats more but unsupported.

🏆 Your Track 4 deliverable

Build a portfolio-grade, integrative RNA analysis. A strong version:

  • Take a public dataset with both MeRIP-seq (or CLIP) and matched RNA-seq (search GEO, e.g. a METTL3 or YTHDF2 perturbation study).
  • Call m6A peaks (QC: recover DRACH and stop-codon enrichment) and run differential expression.
  • Intersect the methylated transcripts with the differentially expressed ones to propose direct targets, and state the predicted direction (e.g. lose m6A → more stable).
  • Write a short, honest interpretation: what the data support, what they do not, and which experiment would test causality next.
  • Publish it to GitHub with a clear README. This is a genuinely advanced, employable piece of work.

Check your understanding

You find that m6A-methylated transcripts tend to have shorter half-lives than unmethylated ones. A collaborator wants to publish "m6A causes mRNA decay." What is the minimum needed to support a causal claim?
Correct. Correlation between methylation and decay is suggestive but not causal. Causality requires intervention: removing the writer or reader and observing that the destabilization is lost or reversed on the affected transcripts. Repeating a correlation does not upgrade it to causation.
After METTL3 knockdown, 1,200 genes change expression. How should you define the credible DIRECT m6A targets among them?
Exactly. A writer knockdown perturbs the whole network, so most changed genes are indirect. Intersecting the differentially expressed list with methylation (and binding) data, and checking the direction of change, isolates the defensible direct targets. This intersection logic is the core of integrative analysis.
Which scenario gives the MOST credible mechanistic conclusion about an RNA-binding protein's effect on its targets?
Right. Credibility comes from orthogonal, independent assays agreeing: direct binding (CLIP), a causal perturbation, and a measured functional consequence, all pointing at the same transcripts. One deep dataset, however large, cannot substitute for convergent independent evidence.
Why does combining m6A maps with RNA-seq after a METTL3 knockdown make a stronger argument than either dataset alone?
Correct. An m6A map shows where the mark sits; the knockdown RNA-seq shows what happens to expression when the writer is gone. Integrating them connects location to consequence, which is far more convincing than correlation in one dataset.
When integrating RNA evidence, what makes a candidate a more credible DIRECT target of an RNA-binding protein?
Exactly. Direct targets should show physical binding (a CLIP or IP peak) and a functional response to knockdown or knockout. Requiring both pieces of orthogonal evidence filters out indirect, downstream effects.

Sources & further reading

  1. Wang X, et al. N6-methyladenosine-dependent regulation of messenger RNA stability (YTHDF2 → decay). Nature, 2014.
  2. Wang X, et al. N6-methyladenosine modulates messenger RNA translation efficiency (YTHDF1). Cell, 2015.
  3. Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol, 2019.
  4. Van Nostrand EL, et al. A large-scale binding and functional map of human RNA-binding proteins (ENCODE integrative analysis). Nature, 2020.

Last reviewed: June 2026.

Track 4 complete

Back to the roadmap and your next track →